Atypical Hemolytic Uremic Syndrome Clinical Trials in Ranica, BG
3 recruitingRanica, BG, Italy
Showing 1–3 of 3 trials
Recruiting
Phase 3
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals50 enrolled31 locationsNCT05935215
Recruiting
Not Applicable
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
HealthyAtypical Hemolytic Uremic SyndromeMembranoproliferative Glomerulonephritis+1 more
Mario Negri Institute for Pharmacological Research105 enrolled1 locationNCT05996731
Recruiting
Not Applicable
Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy
Atypical Hemolytic Uremic Syndrome
Mario Negri Institute for Pharmacological Research112 enrolled1 locationNCT05805202